EMA 发布《胃肠道相互作用研究指南》草案并公开征求意见
Draft guideline on the investigation of interactions in the gastrointestinal tract
CHMP 于 2026 年 6 月 15 日通过 EMA《胃肠道相互作用研究指南》草案(EMA/136069/2026)并放行公开征求意见,征求意见自 2026 年 9 月 11 日开始,截止 2026 年 12 月 31 日。
草案列出食物、胃内pH与抑酸剂、辅料等因素影响吸收时的研究与结果解读建议,可供定位需核对的章节。
PDF 文字版;图形和原始排版请参阅官方 PDF。
第 1 页
1 15 June 2026
2 EMA/136069/2026
3 Committee on Medicines for Human Use (CHMP)
4 Guideline on the investigation of interactions in the
5 gastrointestinal tract
6 Draft
7
8
9
Draft agreed by Methodology Working Party (MWP), Quality
March 2026
Working Party has been consulted
Adopted by CHMP for release for consultation 15 June 2026
Start of public consultation 11 September 2026
End of consultation (deadline for comments) 31 December 2026
10
11
Comments should be provided using this EUSurvey form. For any technical issues, please contact
the EUSurvey Support.
12
Keywords Gastrointestinal tract, interaction, food, gastric pH, formulation
13
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.
第 2 页
14 Guideline on the investigation of interactions in the
15 gastrointestinal tract
16 Table of contents
17 1. Introduction (background) ...................................................................... 3
18 2. Scope....................................................................................................... 3
19 3. Legal basis and relevant guidelines ......................................................... 4
20 4. Investigation of interactions in the gastrointestinal tract ....................... 4
21 4.1. Effects of food intake on the pharmacokinetics of the investigational drug ................... 4
22 4.2. Gastric pH: drug-drug interaction with acid reducing agent ........................................ 6
23 4.3. Gastric emptying or intestinal motility ..................................................................... 9
24 4.4. Excipients ............................................................................................................ 9
25 4.5. Complex formation ............................................................................................. 10
26 4.6. Enterohepatic recirculation .................................................................................. 10
27 5. Reporting and interpretation ................................................................. 11
28 6. Risk assessment and management ........................................................ 11
29
30
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 2/12
第 3 页
31 Executive summary
32
33 This guideline provides recommendations with regards to situations where the absorption of a drug
34 from a medicinal product is altered by extrinsic factors in the gastrointestinal tract. Recommendations
35 are provided on design, conduct and interpretation of in vitro and clinical absorption-related interaction
36 studies. Treatment recommendations based on the clinical relevance of the interactions and the
37 possibility to make dose adjustments or treatment monitoring are addressed.
38 1. Introduction (background)
39 Patients are often prescribed more than one medicinal product and interactions between the medicines
40 (drug-drug interactions (DDI)), sometimes lead to adverse events or alternatively can partially or
41 completely negate treatment efficacy. The ageing European population, in which polypharmacy is more
42 frequent, increases the likelihood of such interactions. The aim of interaction studies performed on new
43 medicinal products is to gain knowledge of how the new medicinal product affects the safety and
44 efficacy of other medicinal products and vice versa.
45 Interactions in the upper gastrointestinal tract can result from extrinsic factors affecting the absorption
46 of orally administered medicinal products. In addition to gastric pH changes, food intake, product
47 formulation and formation of complexes or chelates can affect the intestinal absorption of a drug and
48 this may have consequences for efficacy or safety.
49 On 30 November 2024, ICH M12 Guideline on drug interaction studies (EMA/CHMP/ICH/652460/2022)
50 formally superseded EMA Guideline on the investigation of drug interactions Revision 1
51 (CPMP/EWP/560/95/Rev. 1 Corr. 2**) which had been in effect since 1 January 2013. ICH M12 focuses
52 on pharmacokinetic drug interactions mediated by metabolic enzymes and drug transporters and as
53 such, does not address drug interactions mediated in the upper gastrointestinal part to the same
54 extent that the EMA guideline did. However, the latter interactions are an important component of
55 evaluating a new drug’s interaction potential.
56 This document, therefore, describes the investigation of absorption related interactions affecting the
57 investigational drug through extrinsic factors in the gastrointestinal tract. This includes advice on study
58 design, presentation of study results and translation of these results to treatment recommendations in
59 the labelling of the medicinal product.
60 2. Scope
61 The scope of this guideline is to provide advice and recommendations on how to evaluate the
62 absorption interaction potential of a new medicinal product in the gastrointestinal tract e.g. due to
63 gastric pH change, formation of complexes or chelates and investigation of food effect. The
64 recommendations may also be applicable to changes in product formulations or method of
65 administration.
66 • The guideline mostly describes interactions with the new medicinal product as an object,
67 however, for some aspects (e.g. effect on gastric emptying, effect of excipients) the potential
68 influence of the new medicinal product on the exposure of another medicinal product is also
69 addressed.
70 • The guideline primarily applies to systemically acting active substances that need to be
71 absorbed to exert their pharmacological effect. Many of the recommendations can also be
72 considered for medicinal products that are locally applied and locally acting in the
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 3/12
第 4 页
73 gastrointestinal tract, as many of the interactions described are also likely to affect the
74 concentration of the active substance in the gastrointestinal tract.
75 • The guideline covers mainly orally administered medicinal products, but some aspects (e.g.
76 effect of gastric emptying and motility) may be applicable also to other routes of
77 administration.
78 • Drug interactions mediated by metabolic enzymes and drug transporters in the intestinal cells
79 are not included in this guideline as these are covered in ICH M12.
80 3. Legal basis and relevant guidelines
81
82 This guideline should be read in conjunction with the introduction and general principles (4) of the
83 Annex I to Directive 2001/83/EC as amended, as well as European and ICH guidelines for conducting
84 clinical trials, including
85 – ICH M12 Guideline on drug interaction studies (EMA/CHMP/ICH/652460/2022)
86 – EC SmPC Guideline (London, 20 November 2008)
87 – Guideline on the requirements to the chemical and pharmaceutical quality documentation
88 concerning investigational medicinal products in clinical trials (EMA/CHMP/QWP/545525/2017
89 Rev. 2)
90 – Guideline on quality of oral modified release products (EMA/CHMP/QWP/428693/2013)
91 – Guideline on the clinical evaluation of modified release dosage forms (EMA/CHMP/EWP/280/96
92 Rev1)
93 – Guideline on pharmaceutical development of medicines for paediatric use
94 EMA/CHMP/QWP/805880/2012 Rev. 2
95 – Reflection paper on the pharmaceutical development of medicines for use in the older
96 population EMA/CHMP/QWP/292439/2017
97 4. Investigation of interactions in the gastrointestinal tract
98 The investigation of absorption interactions serves to identify situations where the solubility,
99 dissolution or absorption of a drug is altered by extrinsic factors leading to a change in the rate and/or
100 extent of drug absorption to an extent which may affect the efficacy or safety of the drug. Studies of
101 the effect of food, increased gastrointestinal pH, complex binding, gastrointestinal motility, and
102 modified intestinal active transport should be considered.
103 General principles regarding DDI study design and evaluation as well as reporting and interpretation of
104 clinical DDI results presented in ICH M12 are generally applicable also for the evaluation of interactions
105 in the gastrointestinal tract.
106 4.1. Effects of food intake on the pharmacokinetics of the investigational
107 drug
108 Food changes temporarily the physiological conditions in the human gastrointestinal tract by increasing
109 the gastric pH, slowing the gastric emptying, increasing luminal bile salts and enzymes and increasing
110 intestinal and hepatic perfusion. In this way, food may affect the rate and extent of absorption of a
111 drug, e.g. by slower release from the stomach, by changes in solubility, in contact with enterocytes
112 and in first pass-effect.
113 The effect of food intake on the rate and extent of absorption of the active substance of an orally
114 administered medicinal product should be investigated as early as possible during drug development to
115 optimise dose finding and to ensure appropriate food recommendations in phase 3 clinical studies. In
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 4/12
第 5 页
116 general, intake of a medicinal product in relation to meal times should aim at minimising variability of
117 exposure and obtaining safe and efficacious exposure, without causing unnecessary restrictions for the
118 patient. Another common reason for recommending intake with food is gastrointestinal tolerability
119 issues.
120 Although it is recommended to evaluate the food effect early in clinical development, the food effect of
121 the commercial formulation also needs to be addressed if formulation changes have been made. The
122 food effect of the commercial formulation should be investigated in a food effect study or it needs to be
123 adequately justified that a similar food effect is expected e.g. based on the nature of the formulation
124 changes performed, the evaluated food effect of earlier clinical development formulations and the
125 solubility of the drug and bioavailability of the active substance.
126 In general, the bioavailability of the active substance of a new medicinal product should be compared
127 under the most extreme situations i.e., in fasted state and with a high-fat meal. When a clinically
128 significant effect of a high-fat meal is found, further food interaction studies may be needed (see
129 section on Study design). On the other hand, if there is no clinically relevant effect of a high-fat meal
130 on the absorption of the active substance compared to fasted conditions, it can generally be assumed
131 that other types of meals will not affect the absorption of the active substance.
132 Study design
133 In a standard cross-over food effect study, a single dose of the investigational medicinal product is
134 administered with 150-250 ml of water after a 10-hour fasting period either without food, or 30
135 minutes after intake of a meal has started. Thereafter, the subjects should refrain from food for at
136 least 4 hours after drug administration and all food intakes should be standardised for at least 12
137 hours post-dose. The recommended composition of a high fat meal and a moderate fat/calorie meal
138 are described below. In case a single dose study cannot be performed in healthy subjects or patients, a
139 multiple dose, steady-state study with administration of doses of the medicinal product under fasting
140 and fed conditions, respectively, may be satisfactory.
141 When a clinically significant food effect is found (section 5), further food interaction studies may be
142 warranted to support recommendations regarding type of food and the timing of drug administration in
143 relation to food intake.
144 Dose
145 Usually, a therapeutic dose is evaluated in the food effect study. Any dose in the therapeutic dose
146 range can be selected for the food effect study when the pharmacokinetics is dose proportional. The
147 results obtained with one dose can be extrapolated to the other doses. If the pharmacokinetics is non-
148 linear with less than dose-proportional increases in the AUC or Cmax when increasing the dose, it is
149 recommended to investigate the effect of food on both the highest and lowest doses of the therapeutic
150 range. If the pharmacokinetics is non-linear with larger than dose-proportional increases, studying the
151 food effect with the highest dose is generally sufficient.
152 Strengths
153 For the food effect study the clinical dose range rather than the strengths are considered. In rare cases
154 that the various strengths deviate markedly in composition, food effect of more than one strength may
155 need to be investigated. In such case, excipients, availability of pharmacokinetic data with various
156 strengths and whether a food effect has been observed on other strength(s), solubility of the drug and
157 linearity of the pharmacokinetics should be considered. The strengths that deviate most in composition
158 should be selected if an additional food effect study is deemed necessary.
159 Standardised meals
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 5/12
第 6 页
160 The high fat meal should contain 800-1000 kcal with 500-600 kcal from fat and 250 kcal from
161 carbohydrates. A standard test high fat meal can be composed of: two eggs fried in butter, two strips
162 of bacon, two slices of toast with butter, 120 ml of hash brown potatoes and 240 ml of whole milk.
163 Substitutions in this test meal can be made as long as the meal provides similar amounts of calories
164 from protein, carbohydrate, and fat and has comparable meal volume and viscosity.
165 A moderate fat/calorie meal can contain approximately 400-500 kcal with fat contributing to ca. 150
166 kcal.
167 Other considerations
168 When the effect of food cannot be studied in healthy subjects but has to be studied in patients, the
169 type of meal recommended for the target patient population or a moderate-fat meal can be
170 considered.
171 If physicochemical properties of the drug and in vitro data indicate that complex binding with bivalent
172 cations might become an issue in vivo, the need for a food interaction study with a dairy food product
173 (calcium-rich) should be considered. This should be addressed especially when the medicinal product is
174 intended for newborns and infants whose diet is different than adults (e.g. 100% milk-based in
175 newborns). See also section 4.5.
176 Some foods or beverages (e.g. grapefruit juice, coffee) have the potential to inhibit or induce intestinal
177 enzymes or transporters and thus can affect the oral bioavailability of an investigational drug. When
178 the mechanism of such interaction is known, interactions with this type of food are usually not
179 investigated in a clinical drug interaction study, but avoidance of this type of food might be
180 recommended in the product information. Consumption of these products prior to and during a food
181 effect or drug drug interaction study is usually excluded or limited.
182 For modified release formulations, advice regarding the investigation of the effect of food or alcohol on
183 drug release are given in guidelines specific for these formulations (see EMA Guideline on
184 pharmacokinetic and clinical evaluation of modified-release dosage forms (EMA/CHMP/EWP/280/96
185 Rev1)).
186 In many cases, it is desirable to be able to administer an oral formulation in alternative ways to
187 patients with difficulties to swallow. For example, a drug product could be opened, crushed,
188 disintegrated in liquid or sprinkled on soft food or administered via a feeding tube. In order to include
189 information on these alternative ways of handling the medicinal product in the Summary of Product
190 Characteristics, supporting data is usually needed. Generally, an in vivo relative bioavailability study is
191 expected unless justified. A justification may include a discussion on Biopharmaceutics Classification
192 System-class, dissolution rate of drug product or available bioequivalence data on other oral
193 formulations and the therapeutic window. The bioavailability study should reflect the intended
194 administration conditions for both the crushed/opened and intact formulation. In addition, quality data
195 should be provided, e.g. to demonstrate a lack of physicochemical interactions between soft food or
196 liquid and the drug product (Guideline on the requirements to the chemical and pharmaceutical quality
197 documentation concerning investigational medicinal products in clinical trials,
198 EMA/CHMP/QWP/545525/2017 Rev. 2; Guideline on pharmaceutical development of medicines for
199 paediatric use, EMA/CHMP/QWP/805880/2012 Rev. 2; Reflection paper on the pharmaceutical
200 development of medicines for use in the older population, EMA/CHMP/QWP/292439/2017).
201 4.2. Gastric pH: drug-drug interaction with acid reducing agent
202 Drugs with in vitro solubility that is markedly pH dependent within the physiological pH range (between
203 1.2 and 6.8), may have their absorption affected by concomitant administration of drugs which change
204 the gastrointestinal pH. If in vitro data indicate that pH-dependent solubility may impact the absorption
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 6/12
第 7 页
205 of the investigational drug, an in vivo DDI study should generally be performed with an appropriate
206 acid reducing agent (ARA). The potential for a pH-dependent DDI should preferably be evaluated early
207 in clinical development to ensure subsequent efficacy and safety for patients.
208 Drugs at the highest risk for a clinically relevant interaction with ARAs are weak-bases with low
209 aqueous intrinsic solubility, where increased gastric pH (i.e. pH>4) can decrease solubility and
210 absorption, potentially leading to loss of efficacy.
211 Absorption of weak-acidic drugs with low solubility at low pH (~1.2) and increased solubility at higher
212 pH may also theoretically be affected by co-administration with an ARA. However, there are currently
213 limited data and the observed effects are generally minor and not considered clinically significant under
214 most circumstances. Therefore, for weak acids the need for a clinical DDI study should be evaluated
215 based on the drug safety profile.
216 In general, if the drug has pH dependent solubility but exhibits high solubility across the physiological
217 pH range, a DDI study with an ARA is not required. If the tested drug is a modified release formulation
218 with a pH-sensitive release mechanism, gastrointestinal pH modification may affect the drug release
219 and consequently the drug absorption. Further recommendations on in vitro and in vivo investigations
220 to conduct are provided in EMA Guideline on quality of oral modified release products
221 (EMA/CHMP/QWP/428693/2013) and EMA Guideline on the pharmacokinetic and clinical evaluation of
222 modified release dosage forms (EMA/CHMP/EWP/280/96 Rev1), respectively.
223 Considerations for study design
224 An in vivo DDI study quantitatively determines the DDI potential of the investigated drug with an ARA.
225 The aim of the study could be either to evaluate the worst-case scenario, or to support alternative
226 dosing regimens to avoid clinical drug-drug interactions. If the purpose of the study is to evaluate the
227 worst-case magnitude of a DDI, the investigated drug and the ARA should be administered when the
228 ARA effects are most pronounced. On the other hand, if the purpose is to support an alternative dosing
229 regimen to avoid clinical DDI, then staggered administration should be applied.
230 Generally, the ARA should be administered at the highest recommended dose under therapeutic
231 conditions with a sufficiently long duration to reach the maximal pharmacodynamic effect. Usually,
232 single dose administration of the investigational drug is adequate unless the absorption is modified
233 following repeated administrations, or if the study is conducted in patients in whom a single
234 administration is not adequate.
235 The interaction study of the investigational drug with an ARA should be conducted under the prandial
236 conditions consistent with the intended clinical use. For investigational drugs intended to be
237 administered in a fasted state, drug interaction studies should thus be conducted under fasted
238 conditions. Conversely, if the investigational drug is intended for administration with food, studies
239 should be conducted under fed conditions using a moderate fat/calorie meal to align with clinical
240 practice.
241 If the investigational drug is to be administered regardless of food intake, studies should still be
242 conducted under fasted conditions, as this represents the worst-case scenario for absorption. For
243 several drugs the impact of ARAs on the absorption is considerably less under fed conditions compared
244 to fasted conditions. When there is a clinically relevant effect of an ARA on the absorption of an
245 investigational drug under fasted conditions and the drug can be administered with and without a
246 meal, applicants are encouraged to evaluate the effect of ARAs also under fed conditions.
247 Selection of the ARAs to be used in the in vivo study should consider the aim of the study, the ARA's
248 properties, including its onset and duration of action, the extent of acid secretion inhibition, and the
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 7/12
第 8 页
249 enzymes involved in its metabolism. Specific considerations for the common pharmacological classes
250 are provided below.
251 – Proton pump inhibitors
252 Proton pump inhibitors (PPIs) are the most commonly prescribed ARAs. PPIs irreversibly bind to H+-K+-
253 ATPase thereby reducing gastric acid production. PPI’s effect on gastric pH is dose-dependent and is
254 more pronounced and lasts longer than the effect of H2 antagonists. The baseline gastric acid
255 secretory capacity may not be restored for up to 24–48 h after discontinuing PPI therapy.
256 In the DDI study, the PPI should be administered for at least 4 days to reach pharmacodynamic steady
257 state. The magnitude of increase of gastric pH and its duration over 24 hours is dependent on the
258 selected PPI and the dose applied. Choice of PPI, dose and timing of dosing between PPI and the
259 medicinal product should be justified.
260 Additionally, if the investigational drug is a CYP2C19 substrate, it should be considered that many
261 proton pump inhibitors (e.g. omeprazole) are CYP2C19 inhibitors.
262 – H2 antagonists
263 H2 antagonists compete with histamine for the H2 receptor. In a DDI study, H2 antagonists should be
264 administered at the therapeutic dosing regimen. Given the rapid onset of action, usually gastric pH is
265 increased 2h post-dosing, and the effect lasts up to approximately 12h, multiple administration is not
266 required to obtain a maximal increase in gastric pH. Hence, a single dose, cross-over study of the new
267 medicinal product with and without H2 antagonist with justified timing between administration of the
268 medicinal product and the H2 antagonist is adequate.
269 It should be noted that some H2 antagonists are weak inhibitors of some CYPs isoforms, and/or
270 transporters.
271 – Antacids
272 Antacids are cationic bases that increase intragastric pH by neutralisation of local acidity. Their onset
273 of action is fast but also short-lived. The timing of the antacid and the investigational drug
274 administrations should be carefully considered.
275 Given the salt nature of antacids, possible complex binding with the investigational drug might occur
276 depending on the physicochemical properties of the investigational product.
277 Study results interpretation
278 DDI study results obtained with an ARA may only be extrapolated within the same pharmacological
279 class. However, if an adequate DDI study conducted with a PPI demonstrates the absence of a
280 clinically significant interaction, extrapolation of this finding to the other ARA classes is considered
281 acceptable. Given the pronounced and prolonged effect of PPIs on gastric pH elevation, well-performed
282 PPI studies are regarded as a worst-case scenario for assessing potential interactions with ARAs.
283 In cases where a study with a PPI indicates a clinically significant alteration in the exposure of the
284 investigated drug, DDI mitigation strategies are encouraged. Further investigation with H2 antagonists
285 or antacids is recommended to support alternative dosing regimens to potentially avoid clinical drug-
286 drug interactions.
287 Modelling and Simulation approach
288 In some cases, the population pharmacokinetic modelling analyses of data from the pivotal clinical
289 trials can be used to gain some information on a potential ARA-interaction, provided that a sufficient
290 number of subjects have received ARAs in the clinical trials. Information on duration of ARA
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 8/12
第 9 页
291 administration should be documented and preferably also information on dose, time of administration
292 as well as prandial state. Whereas time of administration of a PPI might be less critical due to its
293 prolonged effect, inclusion of antacids and H2 antagonists as covariates in the population
294 pharmacokinetic analysis is only possible when timing of administration of the drug in relation to intake
295 of ARAs is well documented. The analysis should preferably be pre-specified, and a stratified covariate
296 analysis, based on the pharmacological class of ARA, on the effect of the ARA on the pharmacokinetics
297 of the drug is performed. Pharmacokinetics of subjects without co-medication with any ARA should be
298 compared to the individual ARA pharmacological classes. ARAs of the different pharmacological classes
299 should not be pooled.
300 Physiologically based pharmacokinetic modelling or semi-mechanistic absorption models may also be
301 used in some cases, provided that the model has been adequately qualified for the appropriate context
302 of use (see ICH M15 Guideline on general principles for model-informed drug development
303 (EMA/CHMP/ICH/496426/2024); Guideline on the reporting of physiologically based pharmacokinetic
304 (PBPK) modelling and simulation (EMA/CHMP/458101/2016)).
305 4.3. Gastric emptying or intestinal motility
306 Certain drugs (e.g. opioids, GLP-1 receptor agonists) and excipients (e.g. polyols) are known to affect
307 gastric emptying or intestinal motility and may thus affect the rate and extent of absorption of
308 concomitantly administered drugs. This is particularly relevant for drugs with a narrow therapeutic
309 window or for medicinal products for whose early onset of action is of clinical relevance. It may also be
310 relevant for modified release formulations or drugs with a limited physiological absorption window,
311 marked permeability limited absorption or significant Cmax related effects.
312 If the investigational drug affects the gastrointestinal motility or gastric emptying, the interaction
313 potential should be considered and, if indicated, the effect should be studied on relevant drugs (e.g.
314 paracetamol as probe substrate in case of effects on gastric emptying). It should be noted that effects
315 on the gastrointestinal motility are often due to a systemic effect and may be caused also by
316 parenterally administered medicinal products e.g. GLP-1 receptor agonists.
317 4.4. Excipients
318 Excipients, such as diluents, fillers, binders, lubricants, coatings, solvents, flavouring and dyes, are
319 often inert substances used to manufacture a reproducible, stable drug product. However, some
320 excipients can significantly influence the absorption characteristics of drugs through mechanisms such
321 as an impact on solubility, dissolution or stability, a change in intestinal permeability (including
322 transporters), modulation of the gastrointestinal motility, or site-specific delivery of a drug.
323 Effect of an excipient on concomitantly used medicinal products
324 Widely used excipients such as macrogols, polysorbates, cyclodextrins, sodium laurilsulfate,
325 macrogolglycerol ricinoleate and tocofersolan, are used to improve the solubility and dissolution of a
326 drug and thus improve absorption of the drug. Whilst improving the absorption of the drug of interest,
327 the excipient may inadvertently impact the drug absorption of concomitantly administered medicinal
328 products. Also sugar-alcohols such as mannitol and sorbitol, which are frequently used as sweeteners
329 to mask poor taste of the active substance, are known to affect the absorption of drugs (see section
330 4.3). The risk that a given excipient will influence the absorption of another co-administered drug
331 should be assessed mechanistically by considering:
332 • the amount of excipient used,
333 • the mechanism by which the excipient may affect absorption,
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 9/12
第 10 页
334 • absorption properties (rate, extent and mechanism of absorption of the concomitantly administered
335 drug).
336 For most commonly used excipients, literature data describing the potential impact on the absorption
337 of drugs is expected to be sufficient to provide relevant information in the Summary of Product
338 Characteristics, when needed. However, if the risk of a clinically relevant effect of the excipient on the
339 absorption of concomitantly used drugs cannot be estimated using other data, an in vivo interaction
340 study is recommended.
341 Distinct function of excipient to increase absorption of the investigational drug
342 Sometimes an excipient is claimed to have a more distinct function on the absorption of a drug
343 resulting in a specific formulation characteristic, e.g. salcaprozate sodium as absorption enhancer for
344 peptides or tartaric acid to create a micro-acid environment in the stomach while the gastric pH is
345 increased by ARAs. The mechanism by which such an excipient is expected to enhance the
346 bioavailability of the investigational drug should be discussed and a comparative pharmacokinetic
347 study with and without the excipient is recommended to demonstrate the impact of the excipient on
348 the bioavailability of the drug. The design of the study with regard to the use of fasting and/or fed
349 conditions depends on the dosing instructions in the Summary of Product Characteristics.
350 4.5. Complex formation
351 Other mechanisms of interference with drug absorption, such as complex binding should also be
352 considered. For example, simultaneous administration of multivalent cation-containing drugs and
353 mineral supplements (e.g. calcium, magnesium, aluminium, iron) or polymeric phosphate binders (e.g.
354 sevelamer or lanthanum carbonate), reduces the absorption of many orally administered drugs
355 including some antibiotics.
356 If physicochemical properties of the drug and in vitro data indicate that complex binding might become
357 an issue in vivo, an in vivo interaction study should be considered. Also, a time interval between
358 administration of the two medicinal products so that the interaction is minimal or not present should be
359 proposed based on in vivo data or other justification.
360 4.6. Enterohepatic recirculation
361 Bioavailability of drugs that undergo enterohepatic recirculation may be reduced in situations when the
362 enterohepatic recirculation is affected. For example, bile acid sequestrants can decrease the absorption
363 of drugs that undergo hepatic recirculation by mechanisms such as complex formation or decreased
364 solubility. Additionally, several oral antibiotics may interfere with the enterohepatic recirculation of
365 drugs excreted in the bile as glucuronide-metabolites. These metabolites are further deglucuronidated
366 by β-glucuronidase enzymes present in intestinal bacteria allowing the parent drug to be reabsorbed
367 into the circulation. Antibiotics, which kill those bacteria, prevent the glucuronide-metabolite to be
368 converted back to the parent drug, and in this way lower the bioavailability of the parent drug.
369 For drugs for which significant enterohepatic recirculation is suspected (e.g. substantial secondary
370 peaks in the pharmacokinetic curve, bile excretion in animals...etc), clinical DDI interaction studies
371 should be conducted on a case-by-case basis, considering contribution of enterohepatic recirculation to
372 the oral bioavailability, the therapeutic window as well as the likelihood of co-administration of the
373 medicine with bile acid sequestrants or/and oral antibiotics.
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 10/12
第 11 页
374 5. Reporting and interpretation
375 For the food or drug interaction studies, the following exposure measures should be determined for
376 each subject: AUC0-t, Cmax, and time to Cmax (tmax). These parameters for metabolites, when
377 measured, should also be presented. Pharmacokinetic results of the interaction studies should be
378 reported as the geometric mean ratio of the observed pharmacokinetic exposure measures with and
379 without food / the precipitant drug and the associated 90 percent confidence interval. Measures of the
380 observed variability of the interaction, such as the range of AUC or Cmax ratios for individuals in a
381 cross-over study, should be reported.
382 Results from pharmacodynamic endpoints, whenever available, should be reported and summarised.
383
384 The results of the interaction study should be discussed considering the therapeutic window (no-effect
385 boundaries) of the medicinal product (ICH M12 guideline on drug interaction studies, section 5.3.1).
386 If there is no clinically relevant food effect but the medicinal product is to be administered under
387 certain fasted or fed conditions for tolerability or pharmacodynamic reasons, the reason for the food
388 restriction should be explicitly indicated in the Summary of Product Characteristics section 4.2 ‘Method
389 of administration’.
390
391 6. Risk assessment and management
392 DDI management strategies such as interaction prevention and risk minimisation strategies, should be
393 based on the assessment of interaction risk from altered drug absorption, with relevant principles from
394 ICH M12 applying.
395 Since the interactions described in this guideline involve absorption mediated interactions, these
396 interactions are limited by the time span in the gastrointestinal tract. Many interactions could be
397 mitigated by staggering the administration between the two medicinal products. However, for an
398 interaction with the long acting proton pump inhibitors as precipitant, this is usually not an option.
399 The risk of adverse events and reduced efficacy should be discussed in the registration dossier for a
400 patient erroneously taking the medicinal product occasionally under the not-recommended food
401 conditions when there is a clinical relevant food effect and the medicinal product should be
402 administered either under fasted or fed conditions. If there is considered a risk, risk minimisation and
403 communication of risks should be applied.
404 In general, DDI management strategies should ensure that drug concentrations of the investigational
405 drug fall within the no-effect boundaries. The risk assessment and development of risk minimization
406 strategies should consider the following factors:
407 – The exposure-response relationships for safety and efficacy;
408 – The variability of the observed DDI data, if available;
409 – The expected duration of concomitant medicinal product use (e.g., acute, short-term, or
410 chronic use of one or both medicinal products);
411 – The anticipated timing of the introduction of the concomitant medication;
412 – The mechanism of the DDI;
413 – The availability of monitoring parameters (e.g., therapeutic drug monitoring, laboratory tests);
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 11/12
第 12 页
414 – The ability to interrupt the investigational medicinal product or concomitant interacting
415 medication and the availability of other therapeutic options for either drug;
416 – The clinical importance of the relevant adverse outcome relative to the clinical benefit of the
417 medicinal products;
418 After considering the items above, DDI management strategies can include the following:
419 - Contraindication or avoiding concomitant use;
420 – Temporarily discontinuing one of the interacting medicinal products;
421 – Modifying the dosing regimen of one of the medicinal products;
422 – Staggering drug administration (e.g., administer the investigational medicinal product at a
423 different time than a concomitant medicinal product);
424 – Replacing one of the interacting drugs with a drug not expected to interact;
425 – Implementing specific monitoring strategies (e.g., therapeutic drug monitoring, laboratory
426 testing).
427 Any proposed risk minimisation measures or alternative strategies for mitigating potential
428 gastrointestinal interactions should be documented in the Summary of Product Characteristics (SmPC)
429 in accordance with the EC SmPC guideline (2009).
Guideline on the investigation of interactions in the gastrointestinal tract
EMA/136069/2026 Page 12/12
来源:EMA 官方医药监管信息 · ema.europa.eu